-
公开(公告)号：US20060029546A1
公开(公告)日：2006-02-09
申请号：US10912971
申请日：2004-08-06
CPC分类号： A61K49/0008 , G01N33/6896 , G01N2333/70571 , G01N2800/302 , G01N2800/52
摘要： The invention relates to materials and methods of identifying modulators of N-methyl-D-Aspartate (NMDA) receptor phosphorylation and function, including anti-schizophrenic agents that modulate NMDA receptor function. The methods of the invention utilize animal models of schizophrenia and cell-based assays to identify modulators of NMDA function. The invention further provides anti-schizophrenic agents identified by these methods. The invention relates to methods of treating schizophrenia using the modulators and anti-schizophrenic agents identified by the methods of the invention.
摘要翻译： 本发明涉及鉴定N-甲基-D-天门冬氨酸（NMDA）受体磷酸化和功能的调节剂的材料和方法，包括调节NMDA受体功能的抗精神分裂剂。 本发明的方法利用精神分裂症的动物模型和基于细胞的测定来鉴定NMDA功能的调节剂。 本发明还提供了通过这些方法鉴定的抗精神分裂药物。 本发明涉及使用通过本发明的方法鉴定的调节剂和抗精神分裂症药物治疗精神分裂症的方法。
-
2.发明授权Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation 失效用于治疗炎症的LTA4H的二芳基取代的杂环抑制剂公开(公告)号：US08598359B2
公开(公告)日：2013-12-03
申请号：US12136874
申请日：2008-06-11
申请人： Vincent Sandanayaka , Jasbir Singh , Mark Gurney , Bjorn Mamat , Peng Yu , Louis Bedell , Lei Zhao , Rama K. Mishra
发明人： Vincent Sandanayaka , Jasbir Singh , Mark Gurney , Bjorn Mamat , Peng Yu , Louis Bedell , Lei Zhao , Rama K. Mishra
IPC分类号： C07D211/20 , A61K31/445
CPC分类号： C07D403/12 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/26 , C07D207/263 , C07D207/46 , C07D211/22 , C07D241/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/12
摘要： The present invention relates to a chemical genus of biaryl substituted heterocycle inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders. The compounds have general formula Ψ: An example is
摘要翻译： 本发明涉及可用于治疗和预防和预防炎性疾病和病症的LTA4H（白三烯A4水解酶）的联芳基取代的杂环抑制剂的化学属。 化合物具有通式Psi：一个例子
-
公开(公告)号：US20090042900A1
公开(公告)日：2009-02-12
申请号：US11832255
申请日：2007-08-01
申请人： Jasbir Singh , Mark Gurney
发明人： Jasbir Singh , Mark Gurney
IPC分类号： A61K31/517 , A61P19/00 , C07D239/84 , C07D401/14
CPC分类号： C07D239/95 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： 2,4-Diaminoquinazolines of formula (I) are provided herein and are useful for treating spinal muscular atrophy (SMA).
摘要翻译： 本文提供式（I）的2,4-二氨基喹唑啉，可用于治疗脊髓性肌萎缩（SMA）。
-
4.发明申请Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy 审中-公开持续释放制剂和用于人类治疗的白三烯合成抑制剂的给药方案公开(公告)号：US20060257481A1
公开(公告)日：2006-11-16
申请号：US11407458
申请日：2006-04-20
申请人： Mark Gurney , Hakon Hakonarson
发明人： Mark Gurney , Hakon Hakonarson
CPC分类号： A61K31/472 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2866 , A61K31/47
摘要： The invention relates to improved materials and methods for therapy to inhibit production of leukotrienes, and all therapeutic applications thereof.
摘要翻译： 本发明涉及用于抑制白三烯生产的治疗的改进的材料和方法及其所有治疗应用。
-
公开(公告)号：US20050282855A1
公开(公告)日：2005-12-22
申请号：US10769744
申请日：2004-01-30
CPC分类号： A61K31/47 , A61K38/00 , C07K14/4705 , C12Q1/6883 , C12Q2600/156 , G01N2800/324
摘要： Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.
-
6.发明授权公开(公告)号：US06844148B1
公开(公告)日：2005-01-18
申请号：US09668314
申请日：2000-09-22
IPC分类号： A61P25/28 , C07K14/47 , C12N1/21 , C12N9/64 , C12N15/57 , C12Q1/37 , C12Q1/00 , C07K14/00 , C12Q1/25
CPC分类号： C12N9/6478 , C07K14/4711 , C07K2319/00 , C12N2799/026 , C12Q1/37 , G01N2333/96472
摘要： The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. An enzyme that cleaves the α-secretase site of APP also is provided. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
摘要翻译： 本发明提供用于切割APP蛋白和相关核酸，肽，载体，细胞和细胞分离物和测定的β分泌酶切割位点的酶和酶程序。 还提供了切割APP的α-分泌酶位点的酶。 本发明还提供了修饰的APP蛋白和相关核酸，肽，载体，细胞和细胞分离物以及特别可用于鉴定用于治疗或预防阿尔茨海默病的候选治疗剂的测定。
-
7.发明授权Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment 失效心肌梗塞，中风和PAOD的易感基因; 治疗方法公开(公告)号：US07851486B2
公开(公告)日：2010-12-14
申请号：US10830477
申请日：2004-04-22
IPC分类号： A61K31/47
CPC分类号： C12Q1/6883 , A61K38/00 , C07K14/4705 , C12Q2600/156 , G01N2800/324
摘要： Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.
摘要翻译： 公开了心肌梗塞（MI）和染色体13q12上的位点的连锁。 特别地，通过遗传关联分析将该基因内的FLAP基因显示为MI和ACS以及中风和PAOD的易感基因。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。
-
8.发明申请BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION 失效LTA4H用于治疗炎症的BIARYL取代的杂合物抑制剂公开(公告)号：US20090163462A1
公开(公告)日：2009-06-25
申请号：US12136874
申请日：2008-06-11
申请人： Vincent SANDANAYAKA , Jasbir Singh , Mark Gurney , Bjorn Mamat , Peng Yu , Louis Bedell , Lei Zhao , Rama K. Mishra
发明人： Vincent SANDANAYAKA , Jasbir Singh , Mark Gurney , Bjorn Mamat , Peng Yu , Louis Bedell , Lei Zhao , Rama K. Mishra
IPC分类号： A61K31/40 , C07D207/04 , C07D207/16 , C07D401/06 , A61K31/44 , A61K31/454 , A61K31/5377 , A61P29/00 , A61K31/397 , A61K31/495 , A61K31/445 , C07D211/06 , C07D241/04 , C07D413/12
CPC分类号： C07D403/12 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/26 , C07D207/263 , C07D207/46 , C07D211/22 , C07D241/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/12
摘要： The present invention relates to a chemical genus of biaryl substituted heterocycle inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders. The compounds have general formula Ψ: An example is
摘要翻译： 本发明涉及可用于治疗和预防和预防炎性疾病和病症的LTA4H（白三烯A4水解酶）的联芳基取代的杂环抑制剂的化学属。 化合物具有通式Psi：一个例子
-
9.发明申请公开(公告)号：US20090162883A1
公开(公告)日：2009-06-25
申请号：US12274115
申请日：2008-11-19
CPC分类号： C07K14/4711 , C12N9/6478 , C12N2799/026 , C12Q1/37 , G01N2333/96472
摘要： The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. An enzyme that cleaves the α-secretase site of APP also is provided. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
摘要翻译： 本发明提供用于切割APP蛋白和相关核酸，肽，载体，细胞和细胞分离物和测定的β分泌酶切割位点的酶和酶程序。 还提供了切割APP的α-分泌酶位点的酶。 本发明还提供了修饰的APP蛋白和相关核酸，肽，载体，细胞和细胞分离物以及特别可用于鉴定用于治疗或预防阿尔茨海默病的候选治疗剂的测定。
-
10.发明申请ARYL SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE 审中-公开ARYL SULFONAMIDE PERI-取代的BICYCLICS FOR OCCLUSIVE ARTERY DISEASE公开(公告)号：US20090075985A1
公开(公告)日：2009-03-19
申请号：US12264053
申请日：2008-11-03
申请人： Jasbir Singh , Mark Gurney , Georgeta Hategan
发明人： Jasbir Singh , Mark Gurney , Georgeta Hategan
IPC分类号： A61K31/4245 , C07D409/14 , C07D409/12 , C07D413/14 , A61K31/4155 , A61P29/00 , A61P9/00 , A61K31/519 , A61K31/366 , A61K31/5415 , A61K31/444 , A61K31/415 , A61K31/365 , A61K31/4418 , A61K31/40 , A61K31/505 , A61K31/4365 , A61K31/445 , A61P25/00 , A61K31/404 , C07D401/02 , C07D209/04 , A61K31/47
CPC分类号： C07D209/08 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/14
摘要： Aryl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:
摘要翻译： 公开了用于治疗或预防前列腺素介导的疾病或病症的芳基磺酰胺，邻位取代的稠合双环化合物。 化合物具有通式A的代表性实例是：
-
-
-
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.041 秒)
